排名前五的靶点	数量

TfR1(转铁蛋白受体1)	3
TNFR2(肿瘤坏死因子受体2)	3
4-1BB x CD3 x DLL3	2
OX40(肿瘤坏死因子受体超家族成员4)	2
Siglec-15(唾液酸结合免疫球蛋白样凝集素-15)	2

关联

项与百奥赛图（北京）医药科技股份有限公司相关的药物

Recombinant human anti-OX40 monoclonal antibody(Eucure Pharmaceutical Technology (Beijing) Co Ltd)

重组抗OX40人源化单克隆抗体注射液(祐和医药科技（北京）有限公司)

靶点

OX40

作用机制

OX40激动剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

YH-004

靶点

4-1BB

作用机制

4-1BB激动剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

Ciletatug vedotin

靶点

CLDN18.2 x Tubulin

作用机制

CLDN18.2抑制剂 [+1]

在研机构

荣昌生物制药（烟台）股份有限公司 [+2]

原研机构

荣昌生物制药（烟台）股份有限公司

在研适应症

实体瘤 [+6]

非在研适应症

转移性实体瘤 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

项与百奥赛图（北京）医药科技股份有限公司相关的临床试验

NCT06751329

/ Recruiting临床1期

A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors

The goal of study：
The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you.
The purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers.
In Part 2, participants will receive the best dose level that was determined in Part 1 of the study.
The purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug.
Participants will:
Participants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the wellbeing and record any new anticancer therapy they may have started.

开始日期2025-02-17

申办/合作机构

思道医药科技（苏州）有限公司

NCT06475937

/ Recruiting临床1期

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM001 for patients with the advanced solid tumors. DM001 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors.
Participants will have up to 17 visits during the study.There will be up to a 4-week Screening Period followed by a treatment period that will be divided into 3-week cycles/ Participants will have 5 study visits during Cycle 1, 3 visits during Cycles 2 and 3, and 1 visit during subsequent cycles. Participants will have an End of Treatment visit 21 days (+ 7 days) after last dose of study drug and then a follow-up visit 30 days (± 7 days) after the End of Treatment visit.

开始日期2024-10-24

申办/合作机构

思道医药科技（苏州）有限公司

NCT05212922

/ Withdrawn临床2期

An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)

This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab，The study is designed to determine the safety ，tolerability and antitumor activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.

开始日期2023-06-01

申办/合作机构

祐和医药科技（北京）有限公司

100 项与百奥赛图（北京）医药科技股份有限公司相关的临床结果

登录后查看更多信息

0 项与百奥赛图（北京）医药科技股份有限公司相关的专利（医药）

登录后查看更多信息

项与百奥赛图（北京）医药科技股份有限公司相关的文献（医药）

2025-08-25·Sheng wu gong cheng xue bao = Chinese journal of biotechnology

[Evaluation of antibodies against mpox virus M1R].

Article

作者: Liu, Yawen ; Yang, Hua ; Yang, Sai ; Yang, Yi ; Li, Yan ; Xie, Jingshu

The global outbreak of monkeypox in 2022 has aroused widespread concern in public health. To date, the prevention and treatment of monkeypox has mainly relied on smallpox vaccines and drugs. This study aims to screen and obtain therapeutic antibodies with high affinity, neutralizing activity, and protective effects, and provide candidate molecules for the development of specific therapeutic antibodies against monkeypox. Therefore, humanized mice were immunized to screen for antibodies against the envelope protein of the mpox virus. Two M1R-specific antibodies, 12G5 and 12H6, were obtained, with the affinity of 0.095 nmol/L and 0.089 nmol/L, respectively. The 50% reduction of the plaque counts (PRNT₅₀) of 12G5 and 12H6 was (1.821±1.766) μg/mL and (17.605±2.383) μg/mL, respectively. The two antibodies targeted two binding epitopes of M1R. Moreover, 12H6 could protect 60% of mice from death following the vaccinia virus challenge. This study provides research materials for subsequent in-depth studies on the immunoprotection of mpox virus and potential therapeutic strategies.

2025-08-01·ANTIVIRAL RESEARCH

A monoclonal antibody targeting conserved regions of pre-fusion protein cross-neutralizes Nipah and Hendra virus variants

Article

作者: Zhao, Chunhui ; Ge, Pingju ; Zhang, Mengyi ; Li, Tao ; Bai, Yunbo ; Wang, Youchun ; Jiang, Yinan ; Sun, Ziqi ; Su, Xiaodong ; Huang, Weijin ; Xu, Hua ; Tang, Maoling ; Liu, Yawen ; Nie, Jianhui ; Liao, Binfan ; Xie, Jingshu

Nipah virus (NiV) and Hendra virus (HeV) have an extremely high case fatality, leading to hundreds of deaths in several countries around the globe. Belonging to the same genus Henipavirus (HNV), the two species have a high degree of sequence similarity, resulting in cross-neutralizing immunity under favorable conditions. Here, we obtained ten anti-NiV-F monoclonal antibodies using hybridoma technology, and verified that these antibodies had potent neutralizing activities against epidemic NiV strains from different regions using a pseudovirus assay, and the neutralizing concentration reached the nanogram per milliliter level. Moreover, two of the antibodies, NiF03-3C9 and NiF03-2F6, were found to have cross-neutralizing activity against HeV, which was even stronger than that against NiV. Epitope competition analysis revealed two classes of epitopes for these antibodies. Cryo-electron microscopy showed that NiF03-3C9 binds to lateral residues of the prefusion F protein trimer, highly conserved in both Nipah and Hendra. The protective potency of the antibodies was also validated using in vivo pseudovirus infection models of Nipah and Hendra viruses. The mAbs developed in this study and their conserved cross-neutralizing epitopes elucidated by structural analysis may contribute to the control of highly pathogenic HNV outbreaks.

2022-05-13·Briefings in bioinformatics

A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain

Article

作者: Wang, Youchun ; Liu, Shuo ; Yang, Liu ; Shen, Yuelei ; Guo, Yajuan ; Li, Jianhui ; Yu, Changyuan ; Yang, Yi ; Chai, Mengya ; Xu, Lida ; Chen, Lei

Abstract:

Coronavirus disease 2019 pandemic continues globally with a growing number of infections, but there are currently no effective antibody drugs against the virus. In addition, 90% amino acid sequence identity between the S2 subunit of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV S proteins attracts us to examine S2-targeted cross-neutralizing antibodies that are not yet well defined. We therefore immunized RenMab mice with the full-length S protein and constructed a high-throughput antibody discovery method based on single-cell sequencing technology to isolate SARS-CoV-2 S-targeted neutralizing antibodies and cross-neutralizing antibodies against the S2 region of SARS-CoV-2/SARS-CoV S. Diversity of antibody sequences in RenMab mice and consistency in B-cell immune responses between RenMab mice and humans enabled screening of fully human virus-neutralizing antibodies. From all the frequency >1 paired clonotypes obtained from single-cell V(D)J sequencing, 215 antibodies with binding affinities were identified and primarily bound S2. However, only two receptor-binding domain-targeted clonotypes had neutralizing activity against SARS-CoV-2. Moreover, 5' single-cell RNA sequencing indicated that these sorted splenic B cells are mainly plasmablasts, germinal center (GC)-dependent memory B-cells and GC B-cells. Among them, plasmablasts and GC-dependent memory B-cells were considered the most significant possibility of producing virus-specific antibodies. Altogether, using a high-throughput single cell-based antibody discovery approach, our study highlighted the challenges of developing S2-binding neutralizing antibodies against SARS-CoV-2 and provided a novel direction for the enrichment of antigen-specific B-cells.

657

项与百奥赛图（北京）医药科技股份有限公司相关的新闻（医药）

2026-02-01

·医药笔记

勃林格殷格翰：TRPC6抑制剂FSGS二期临床成功

▎Armstrong 2026年1月28日，勃林格殷格翰宣布其全球首创TRPC6抑制剂Apecotrep(BI 764198)治疗局灶性节段性肾小球硬化（FSGS）的二期临床获得积极数据，研究结果发表在柳叶刀期刊上。该二期临床共入组62例FSGS患者，分成4组，分别接受安慰剂、20mg、40mg、80mg Apecotrep治疗，尿蛋白响应率分别为7%、44%、14%、43%。3个剂量组合并计算尿蛋白响应率为34.8%。 TRPC6为一种离子通道蛋白，在人体内各组织或器官广泛表达,在肾小球足细胞也有表达。在局灶性节段性肾小球硬化症（FSGS）中，TRPC6的过度活跃可能导致足细胞丢失和肾功能逐渐下降。总结局灶性节段性肾小球硬化（FSGS）预后极差，约50%的原发性FSGS患者会在5-10年内进展到终末期肾脏病（ESKD），每年因FSGS死亡的病例达0.8例/10万人。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

2026-01-31

·医药笔记

苑东生物：TL1A抗体启动一期临床

▎Armstrong 2026年1月29日，苑东生物子公司优洛生物在药品临床试验登记与信息公示平台网站上注册了EP-0210单抗注射液的一期临床试验。EP-0210的目标适应症为炎症性肠病。从临床注册信息分析，EP-0210应为一款TL1A单抗。 EP-0210采用静脉给药，每两周给药一次，剂量为1-1200mg。总结 TL1A为近年来IBD领域最重要的新靶点，达成多起交易，包括罗氏超70亿美元引进辉瑞/Roivant的RVT-3101，默沙东108亿美元收购Prometheus。赛诺菲15亿美元引进梯瓦的TL1A抗体，三家公司的TL1A抗体都推进到三期临床阶段。TL1A的竞争已经进入第二阶段，以长效抗体和双靶点为主，辉瑞、罗氏都布局了双靶点。国内方面，明济生物长效TL1A抗体授权给艾伯维，华深智药TL1A/IL-23双抗、TL1A/α4β7双抗授权给赛诺菲，先声药业TL1A/IL-23双抗授权给勃林格殷格翰等。三生国健的SSGJ-627、智翔金泰的GR-2303、华深智药的HX-15001、苑东生物的EP-0210陆续推进到临床阶段。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

并购临床2期临床1期临床3期抗体药物偶联物

2026-01-31

·今日头条

抗癌药BNT327：从72亿到800亿，中国创新药的出海价值博弈

> 一款由中国科学家发现、尚在临床验证阶段的抗癌新药，在不到两年内，通过两次国际交易，潜在总价值从约10亿美元飙升至111亿美元（约800亿人民币）。这组悬殊的数字，不仅记录了一次成功的资本运作，更成为中国创新药企在全球产业链中价值兑现与能力短板的生动注脚。 https://p11-doubao-search-sign.byteimg.com/isp-i18n-media/image/a51eb0eeaa100bfb4da904d1e63446ce~tplv-be4g95zd3a-image.jpeg?lk3s=feb11e32&x-expires=1775047514&x-signature=ftZU2QLCZaiyKwF5cuVKaYJNLlM%3D 1. 交易回放：三步走的价值跃迁故事的核心是普米斯生物自主研发的**PD-L1/VEGF双特异性抗体PM8002**（后更名为BNT327）。其价值跃升路径清晰而紧凑： https://p11-doubao-search-sign.byteimg.com/labis/image/4ee9e53fd023c3d9e31112cdc572a6aa~tplv-be4g95zd3a-image.jpeg?lk3s=feb11e32&x-expires=1775047514&x-signature=Z6d88JEFI%2Brn6zu7fa98rVgSREk%3D - **2023年11月**：德国BioNTech以**5500万美元首付款**及不超过10亿美元的里程碑付款，获得了该药物在**除大中华区以外的全球权益**。 - **2024年底**：BioNTech进一步以**9.5亿美元**的总价，全资收购普米斯生物，完全锁定该资产。 - **2025年6月**：BioNTech与美国制药巨头百时美施贵宝（BMS）达成协议，后者支付**15亿美元首付款**，潜在交易总额高达**111亿美元**，以获得BNT327的开发和商业化权益。 > “这是一年半时间不到10亿美元投资撬动90亿美元价值的资本奇迹。” 2. “双刀流”战士的临床数据底气 BNT327的价值根基在于其科学机制与早期数据。作为全球首个进入III期临床的PD-L1/VEGF双抗，它能同时阻断肿瘤免疫逃逸和血管生成两条关键通路。关键的II期临床试验数据为其价值提供了支撑： - 在广泛期小细胞肺癌的一线治疗中，联合化疗的**客观缓解率（ORR）达85.4%**，疾病控制率（DCR）为**97.9%**。 - 中位随访14.5个月时，**72.7%的患者在一年后依然存活**。这些数据使其获得了中国药监局的“突破性治疗品种”认定，并成为交易中的核心筹码。 3. 普米斯的抉择：寒冬中的“理性出售” 对于出售方普米斯生物而言，这并非简单的“贱卖”。2023年前后，中国生物医药行业正经历资本寒冬。公开信息显示，普米斯自成立以来仅完成约**2.4亿美元**的融资。面对动辄需数十亿资金的三期临床试验，资金链压力巨大。 > “普米斯的出让是多重因素下的理性选择……出售早期资产可‘以技换血’。” 在此背景下，获得5500万美元首付款及后续并购的9.5亿美元，为团队提供了确定的现金流，规避了后续高昂且高风险的研发投入，成为一种务实的生存策略。 4. BioNTech的“炼金术”：从资产到价值 BioNTech的角色远非“中间商”那么简单。其核心操作在于利用自身的资本和全球运营能力，快速放大资产价值： - **加速临床开发**：收购后，在一年多时间里推动了**约20项临床研究**落地，覆盖小细胞肺癌、非小细胞肺癌、三阴性乳腺癌等多个大适应症，并迅速进入III期阶段。 - **引入战略合作**：与BMS合作，探索BNT327与ADC（抗体药物偶联物）的联合疗法，进一步挖掘其潜力。这些举措显著降低了药物的开发风险，提升了其商业想象空间，为最终的高价转授权奠定了基础。 5. BMS的算盘：应对专利悬崖的豪赌 BMS愿意支付天价，有其紧迫的战略考量。其王牌肿瘤药**Opdivo（O药）**正面临专利到期压力，急需新的重磅产品填补管线空缺。BNT327在小细胞肺癌等领域的突出数据，恰好能覆盖现有产品的短板。值得注意的是，根据交易细节，BioNTech与BMS将**共同承担50:50的开发和制造成本**，这意味着BioNTech仅出让了部分权益，仍深度参与药物后续价值创造。 6. 超越“青苗”争议：中国药企的出海进阶 BNT327的案例再次引发了对中国创新药“青苗是否被贱卖”的讨论。行业分析指出，交易定价基于项目当前的数据验证与风险分布，而非未来的全部潜力。在资本寒冬中，早期变现为Biotech提供了生存下去的机会。然而，行业也在探索更可持续的出海模式，试图从“一次性卖断”转向长期价值捕获： - **平台化合作**：如百奥赛图通过其RenMice全人抗体小鼠平台，与默克、强生等达成“技术+产品”的阶梯式深度合作，构建“技术出海矩阵”。 - **权益保留与分成**：越来越多交易开始注重保留部分区域权益或设定销售分成条款，以期分享药物上市后的长期收益。中国药企在早期研发上的能力已获国际认可，仅PD-(L)1/VEGF双抗领域，就有多款产品以数十亿乃至上百亿美元的价值授权出海。但要将“青苗”培育为“参天大树”，并掌握其全球商业果实，仍需在**全球多中心临床试验、国际注册申报和市场准入**等关键环节构建核心能力。这场从72亿到800亿的价值博弈，既是一次阵痛，也是一次深刻的行业教育。

引进/卖出并购突破性疗法临床3期临床2期

100 项与百奥赛图（北京）医药科技股份有限公司相关的药物交易

登录后查看更多信息

100 项与百奥赛图（北京）医药科技股份有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年02月04日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

重组抗OX40人源化单克隆抗体注射液(祐和医药科技（北京）有限公司) ( OX40 )	实体瘤更多	临床2期
DM001 ( EGFR x Trop-2 x Tubulin )	晚期恶性实体瘤更多	临床1期
DM-002 (Xadcera Biopharma) ( HER3 x MUC1 x Tubulin )	晚期恶性实体瘤更多	临床1期
DM-005 ( EGFR x Tubulin x c-Met )	晚期恶性实体瘤更多	临床1期
YH-004 ( 4-1BB )	晚期恶性实体瘤更多	临床1期